Published in Oncogene on October 09, 2003
Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 2.74
Current ideas in desmoid tumours. Fam Cancer (2006) 1.82
Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A (2013) 1.57
Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut (2004) 1.42
Rhamm-/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J Cell Biol (2006) 1.28
Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse. BMC Genomics (2007) 1.26
RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J Biol Chem (2010) 1.06
Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. J Biol Chem (2011) 1.05
Hyaluronan and RHAMM in wound repair and the "cancerization" of stromal tissues. Biomed Res Int (2014) 0.89
Specific sizes of hyaluronan oligosaccharides stimulate fibroblast migration and excisional wound repair. PLoS One (2014) 0.88
The roles of hyaluronan/RHAMM/CD44 and their respective interactions along the insidious pathways of fibrosarcoma progression. Biomed Res Int (2013) 0.87
Desmoid tumours: our experience of six cases and review of literature. J Clin Diagn Res (2014) 0.84
The cytoskeletal protein RHAMM and ERK1/2 activity maintain the pluripotency of murine embryonic stem cells. PLoS One (2013) 0.83
Loss of the hyaluronan receptor RHAMM prevents constrictive artery wall remodeling. J Vasc Surg (2013) 0.82
Hyaluronan as a therapeutic target in human diseases. Adv Drug Deliv Rev (2015) 0.81
Overexpression of receptor for hyaluronan-mediated motility (RHAMM) in MC3T3-E1 cells induces proliferation and differentiation through phosphorylation of ERK1/2. J Bone Miner Metab (2011) 0.81
Biology and biotechnology of hyaluronan. Glycoconj J (2015) 0.79
Receptor for Hyaluronic Acid-Mediated Motility is Associated with Poor Survival in Pancreatic Ductal Adenocarcinoma. J Cancer (2015) 0.79
Carcinoma Cell Hyaluronan as a "Portable" Cancerized Prometastatic Microenvironment. Cancer Res (2016) 0.77
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. Nat Genet (2002) 3.60
Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology (2004) 2.90
The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet (2002) 2.69
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology (2006) 2.25
Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell (2011) 2.18
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet (2003) 1.93
Role of CLASP2 in microtubule stabilization and the regulation of persistent motility. Curr Biol (2006) 1.81
Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet (2003) 1.80
Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol (2003) 1.67
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) (2011) 1.64
Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). Genes Chromosomes Cancer (2005) 1.61
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59
cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo. Proc Natl Acad Sci U S A (2008) 1.58
Paneth cells in intestinal homeostasis and tissue injury. PLoS One (2012) 1.57
Cancer stem cells and metastasis. Semin Cancer Biol (2012) 1.50
CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget (2013) 1.48
Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer (2010) 1.47
Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers. J Pathol (2010) 1.44
β-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut (2011) 1.40
APC dosage effects in tumorigenesis and stem cell differentiation. Int J Dev Biol (2004) 1.29
Leiden Open Variation Database of the MUTYH gene. Hum Mutat (2010) 1.28
Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis. Am J Pathol (2008) 1.26
A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA (2004) 1.26
Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum. Am J Med Genet A (2003) 1.23
Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. J Clin Oncol (2008) 1.23
TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol (2005) 1.16
Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res (2009) 1.15
Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability. Genes Chromosomes Cancer (2010) 1.14
Concepts of metastasis in flux: the stromal progression model. Semin Cancer Biol (2012) 1.10
A targeted constitutive mutation in the APC tumor suppressor gene underlies mammary but not intestinal tumorigenesis. PLoS Genet (2009) 1.08
Comprehensive genetic analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan-related phenotypes. Am J Med Genet A (2006) 1.08
Genomic profiling by DNA amplification of laser capture microdissected tissues and array CGH. Nucleic Acids Res (2004) 1.05
Generation of a tightly regulated doxycycline-inducible model for studying mouse intestinal biology. Genesis (2009) 1.03
Chromosomal instability in MYH- and APC-mutant adenomatous polyps. Cancer Res (2006) 1.02
Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol (2012) 1.01
Wnt/Β-catenin and sex hormone signaling in endometrial homeostasis and cancer. Oncotarget (2010) 1.01
The multiple functions of tumour suppressors: it's all in APC. Nat Cell Biol (2003) 1.00
Adenomatous polyposis coli-mediated control of beta-catenin is essential for both chondrogenic and osteogenic differentiation of skeletal precursors. BMC Dev Biol (2009) 0.99
Severe alterations of cerebellar cortical development after constitutive activation of Wnt signaling in granule neuron precursors. Mol Cell Biol (2011) 0.98
Wnt signaling regulates the lineage differentiation potential of mouse embryonic stem cells through Tcf3 down-regulation. PLoS Genet (2013) 0.97
A 10-Mb paracentric inversion of chromosome arm 2p inactivates MSH2 and is responsible for hereditary nonpolyposis colorectal cancer in a North-American kindred. Genes Chromosomes Cancer (2002) 0.95
SET-CAN, the product of the t(9;9) in acute undifferentiated leukemia, causes expansion of early hematopoietic progenitors and hyperproliferation of stomach mucosa in transgenic mice. Am J Pathol (2007) 0.95
Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogenet Genomics (2006) 0.95
EXO1 variants occur commonly in normal population: evidence against a role in hereditary nonpolyposis colorectal cancer. Cancer Res (2003) 0.94
Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids. PLoS One (2011) 0.94
Automated acquisition of stained tissue microarrays for high-throughput evaluation of molecular targets. J Mol Diagn (2003) 0.92
Serrated adenomas and mixed polyposis caused by a splice acceptor deletion in the mouse Smad4 gene. Genes Chromosomes Cancer (2003) 0.91
A new conditional Apc-mutant mouse model for colorectal cancer. Carcinogenesis (2010) 0.90
Premature chromosome condensation revisited: a novel chemical approach permits efficient cytogenetic analysis of cancers. Genes Chromosomes Cancer (2003) 0.89
Targeted deletion of the C-terminus of the mouse adenomatous polyposis coli tumor suppressor results in neurologic phenotypes related to schizophrenia. Mol Brain (2014) 0.87
Identification of quiescent, stem-like cells in the distal female reproductive tract. PLoS One (2012) 0.87
Morphological changes in tumour type after radiotherapy are accompanied by changes in gene expression profile but not in clinical behaviour. J Pathol (2004) 0.86
Of mice and (wo)men: genotype-phenotype correlations in BRCA1. Hum Mol Genet (2003) 0.86
Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human. Am J Pathol (2007) 0.86
Alterations in Wnt-β-catenin and Pten signalling play distinct roles in endometrial cancer initiation and progression. J Pathol (2013) 0.85
Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. Cancer Res (2004) 0.84
The C-terminal domain of the adenomatous polyposis coli (Apc) protein is involved in thyroid morphogenesis and function. Med Mol Morphol (2011) 0.84
Cancer stemness in Wnt-driven mammary tumorigenesis. Carcinogenesis (2013) 0.82
Multiple primary cancer, including transitional cell carcinoma of the upper uroepithelial tract in a multigeneration HNPCC family: molecular genetic, diagnostic, and management implications. Am J Gastroenterol (2003) 0.81
Spectrum of genetic alterations in Muir-Torre syndrome is the same as in HNPCC. Am J Med Genet A (2004) 0.81
Loss of APC function in mesenchymal cells surrounding the Müllerian duct leads to myometrial defects in adult mice. Mol Cell Endocrinol (2011) 0.80
Quiescent stem cells in intestinal homeostasis and cancer. Cell Commun Adhes (2011) 0.80
Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer. Clin Cancer Res (2012) 0.79
American founder mutation for Lynch syndrome. Prevalence estimates and implications. Cancer (2006) 0.78
Some fine-structural findings on the thyroid gland in Apc1638T/1638T mice that express a C-terminus lacking truncated Apc. Med Mol Morphol (2012) 0.78
The nature of intestinal stem cells' nurture. EMBO Rep (2011) 0.77
Cancer stemness in Apc- vs. Apc/KRAS-driven intestinal tumorigenesis. PLoS One (2013) 0.77
Expression analysis of proline rich 15 (Prr15) in mouse and human gastrointestinal tumors. Mol Carcinog (2011) 0.77
Smad4 haploinsufficiency: a matter of dosage. Pathogenetics (2008) 0.76
Generation and characterization of an inducible transgenic model for studying mouse esophageal biology. BMC Dev Biol (2012) 0.75